Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text Full Text (PDF, 606K) PPT slides of all figures Alert me when this article is cited Citation Map Services Email this article Similar articles in this journal Similar articles in PubMed Alert me to new content in the JEM Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Zinser, E. Articles by Steinkasserer, A. Search for Related Content PubMed PubMed Citation Articles by Zinser, E. Articles by Steinkasserer, A. Social Bookmarking                            What's this?

Department of Dermatology, University Hospital Erlangen, D-91052 Erlangen, Germany

Address correspondence to Alexander Steinkasserer, Department of Dermatology, Hartmannstasse 14, University Hospital Erlangen, 91052 Erlangen, Germany. Phone: 49-9131-853-6725; Fax: 49-9131-853- 5799; email: alexander.steinkasserer{at}derma.imed.uni-erlangen.de

CD83 is up-regulated on the surface of dendritic cells (DCs) during maturation and has been widely used as a marker for mature DCs. Recently, we reported the recombinant expression of the extracellular immunoglobulin domain of human CD83 (hCD83ext). Using this soluble form of CD83, allogeneic as well as specific cytotoxic T lymphocyte proliferation could be blocked in vitro. Here we report the functional analysis of soluble CD83 in vivo, using murine experimental autoimmune encephalomyelitis (EAE) as a model. Strikingly, only three injections of soluble CD83 prevented the paralysis associated with EAE almost completely. In addition, even when the EAE was induced a second time, CD83-treated mice were protected, indicating a long-lasting suppressive effect. Furthermore, soluble CD83 strongly reduced the paralysis in different therapeutic settings. Most important, even when the treatment was delayed until the disease symptoms were fully established, soluble CD83 clearly reduced the paralyses. In addition, also when EAE was induced a second time, soluble CD83-treated animals showed reduced disease symptoms. Finally, hCD83ext treatment almost completely reduced leukocyte infiltration in the brain and in the spinal cord. In summary, this work strongly supports an immunosuppressive role of soluble CD83, thereby indicating its therapeutic potential in the regulation of immune disorders in vivo.

Key Words: CD83 • dendritic cells • EAE • T cells • proliferation

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

• Su, L. L., Iwai, H., Lin, J. T., Fathman, C. G. (2009). The Transmembrane E3 Ligase GRAIL Ubiquitinates and Degrades CD83 on CD4 T Cells. J. Immunol. 183: 438-444 [Abstract] [Full Text]  
• Clement, C., Bhattacharjee, P. S., Kaufman, H. E., Hill, J. M. (2009). Heat-Induced Reactivation of HSV-1 in Latent Mice: Upregulation in the TG of CD83 and Other Immune Response Genes and Their LAT-ICP0 Locus. IOVS 50: 2855-2861 [Abstract] [Full Text]  
• Decker, W. K., Xing, D., Li, S., Robinson, S. N., Yang, H., Steiner, D., Komanduri, K. V., Shpall, E. J. (2009). Th-1 polarization is regulated by dendritic-cell comparison of MHC class I and class II antigens. Blood 113: 4213-4223 [Abstract] [Full Text]  
• Kretschmer, B., Luthje, K., Schneider, S., Fleischer, B., Breloer, M. (2009). Engagement of CD83 on B Cells Modulates B Cell Function In Vivo. J. Immunol. 182: 2827-2834 [Abstract] [Full Text]  
• Lechmann, M., Shuman, N., Wakeham, A., Mak, T. W. (2008). The CD83 reporter mouse elucidates the activity of the CD83 promoter in B, T, and dendritic cell populations in vivo. Proc. Natl. Acad. Sci. USA 105: 11887-11892 [Abstract] [Full Text]  
• Luthje, K., Kretschmer, B., Fleischer, B., Breloer, M. (2008). CD83 regulates splenic B cell maturation and peripheral B cell homeostasis. Int Immunol 20: 949-960 [Abstract] [Full Text]  
• Reinwald, S., Wiethe, C., Westendorf, A. M., Breloer, M., Probst-Kepper, M., Fleischer, B., Steinkasserer, A., Buer, J., Hansen, W. (2008). CD83 Expression in CD4+ T Cells Modulates Inflammation and Autoimmunity. J. Immunol. 180: 5890-5897 [Abstract] [Full Text]  
• Prazma, C. M., Yazawa, N., Fujimoto, Y., Fujimoto, M., Tedder, T. F. (2007). CD83 Expression Is a Sensitive Marker of Activation Required for B Cell and CD4+ T Cell Longevity In Vivo. J. Immunol. 179: 4550-4562 [Abstract] [Full Text]  
• Kuwano, Y., Prazma, C. M., Yazawa, N., Watanabe, R., Ishiura, N., Kumanogoh, A., Okochi, H., Tamaki, K., Fujimoto, M., Tedder, T. F. (2007). CD83 influences cell-surface MHC class II expression on B cells and other antigen-presenting cells. Int Immunol 19: 977-992 [Abstract] [Full Text]  
• Lundell, A.-C., Andersson, K., Josefsson, E., Steinkasserer, A., Rudin, A. (2007). Soluble CD14 and CD83 from Human Neonatal Antigen-Presenting Cells Are Inducible by Commensal Bacteria and Suppress Allergen-Induced Human Neonatal Th2 Differentiation. Infect. Immun. 75: 4097-4104 [Abstract] [Full Text]  
• Kummer, M., Turza, N. M., Muhl-Zurbes, P., Lechmann, M., Boutell, C., Coffin, R. S., Everett, R. D., Steinkasserer, A., Prechtel, A. T. (2007). Herpes Simplex Virus Type 1 Induces CD83 Degradation in Mature Dendritic Cells with Immediate-Early Kinetics via the Cellular Proteasome. J. Virol. 81: 6326-6338 [Abstract] [Full Text]  
• Prechtel, A. T., Turza, N. M., Theodoridis, A. A., Steinkasserer, A. (2007). CD83 Knockdown in Monocyte-Derived Dendritic Cells by Small Interfering RNA Leads to a Diminished T Cell Stimulation. J. Immunol. 178: 5454-5464 [Abstract] [Full Text]  
• Dudziak, D., Nimmerjahn, F., Bornkamm, G. W., Laux, G. (2005). Alternative Splicing Generates Putative Soluble CD83 Proteins That Inhibit T Cell Proliferation. J. Immunol. 174: 6672-6676 [Abstract] [Full Text]  

Home | Help | Feedback | Subscriptions | Archive | Search

TABLE OF CONTENTS